To expand the application of the ioTNL model and explore whether it can predict the response to immunotherapy on a panel level, we collected the data of 21 patients with NSCLC with complete clinical outcomes who underwent anti-PD-1/PD-L1 therapy and identified the ioTNL using YuceOne. The gene discussed is CD274; the disease is non-small cell lung carcinoma.